Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Ken Kato, ASCO GI 2021: Long-term Nivolumab Data from the ATTRACTION-1 Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 3rd 2021

touchONCOLOGY were delighted to talk to Prof. Ken Kato to discuss long-term safety and efficacy data from the ATTRACTION-1 study will support the potential role of nivolumab in esophageal squamous cell carcinoma.

The abstract ‘Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up’ (Abstract number 207) was presented at ASCO’s virtual Gastrointestinal Cancers Symposium 2021,15-–17 January 2021.

Questions

  1. Could you tell us a little about the ATTRACTION-1 study and its findings? (0:30)
  2. What has the latest data shown us about the long-term efficacy and safety of nivolumab in advanced esophageal squamous cell carcinoma? (2:07)
  3. Could you give us a brief overview of the ATTRACTION clinical trial programme and other future and ongoing clinical studies in the trial? (4:20)

Disclosures: Prof. Ken Kato has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of ASCO’s Gastrointestinal Cancers Symposium 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup